Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

被引：0
|
作者：
Emery, P. [1 ]
Dudler , J. [2 ]
Smolen, J. [3 ]
Zerbini, C. [4 ]
Burmester, G. [5 ]
Fautrel, B. [6 ]
van de Laar, M. [7 ]
Fleischmann, R. [8 ]
Fakhouri, W. [9 ]
De Leonardis, F. [9 ]
Zhu, B. [9 ]
Kadziola, Z. [9 ]
De La Torre, I [9 ]
Perrier, C. [9 ]
Taylor, P. [10 ]
机构：
[1] Leeds MSK Biomed Chapel Allerton Hosp, Leeds, W Yorkshire, England
[2] HFR Fribourg Hop Cantonal, Fribourg, Switzerland
[3] Med Univ Vienna, Vienna, Austria
[4] Ctr Paulista Invest Sao Paulo Clin, Sao Paulo, Brazil
[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Pierre & Marie Curie, Paris, France
[7] Arthritis Ctr Twente, Enschede, Netherlands
[8] Univ Texas SouthWestern Med Ctr, Dallas, TX USA
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] Univ Oxford, Botnar Res, Headington, England
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 6
引用
收藏
页码：7S / 8S
页数：2
相关论文
共 50 条
  • [41] Two Cases of High Tibial Osteotomy in Patients with Rheumatoid Arthritis Treated with Biologic Disease-modifying Anti-rheumatic Drugs
    Takahara, Yasuhiro
    Nishida, Keiichiro
    Nakashima, Hirotaka
    Ochi, Nobuaki
    Uchida, Yoichiro
    Kato, Hisayoshi
    Itani, Satoru
    Nakamura, Makoto
    Iwasaki, Yuichi
    Tsujimura, Yoshitaka
    ACTA MEDICA OKAYAMA, 2019, 73 (06) : 537 - 542
  • [42] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [43] Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
    Roussy, Jean-Pascal
    Bessette, Louis
    Bernatsky, Sasha
    Rahme, Elham
    Legare, Jean
    Lachaine, Jean
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S855 - S855
  • [44] USE OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS IN QUEBEC, CANADA
    Roussy, J. P.
    Bessette, L.
    Bernatsky, S.
    Rahme, E.
    Legare, J.
    Lachaine, J.
    VALUE IN HEALTH, 2011, 14 (07) : A316 - A316
  • [45] Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients
    Convertino, Irma
    Cazzato, Massimiliano
    Tillati, Silvia
    Giometto, Sabrina
    Gini, Rosa
    Valdiserra, Giulia
    Cappello, Emiliano
    Ferraro, Sara
    Bonaso, Marco
    Bartolini, Claudia C.
    Paoletti, Olga
    Lorenzoni, Valentina
    Filippi, Matteo
    Turchetti, Giuseppe
    Cristofano, Michele
    Blandizzi, Corrado
    Mosca, Marta
    Lucenteforte, Ersilia
    Tuccori, Marco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 488 - 489
  • [46] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Das, Priyam
    Weisenfeld, Dana
    Dahal, Kumar
    De, Debsurya
    Feathers, Vivi
    Coblyn, Jonathan S.
    Weinblatt, Michael E.
    Shadick, Nancy A.
    Cai, Tianxi
    Liao, Katherine P.
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [47] Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
    Priyam Das
    Dana Weisenfeld
    Kumar Dahal
    Debsurya De
    Vivi Feathers
    Jonathan S. Coblyn
    Michael E. Weinblatt
    Nancy A. Shadick
    Tianxi Cai
    Katherine P. Liao
    Arthritis Research & Therapy, 25
  • [48] Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
    Wells, Alvin E.
    Lee, Yvonne C.
    Tundia, Namita
    Suboticki, Jessica
    Chen, Kun
    Friedman, Alan
    Strand, Vibeke
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [49] Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry
    Koh, J. H.
    Lee, S-K
    Kim, J.
    Kim, H-A
    Shin, K.
    Min, J-K
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 269 - 278
  • [50] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
12345